Cover Image
市場調查報告書

深部靜脈血栓症 (DVT):開發中產品分析

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192548
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
深部靜脈血栓症 (DVT):開發中產品分析 Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 62 Pages
簡介

深部靜脈血栓症是指人體深處某靜脈出現的血栓,主要發生在小腿和大腿的大靜脈。主要的症狀,是皮膚變色 (帶紅色) 和下肢痛,下肢的腫脹 (水腫) 、皮膚溫度上升。易罹病素質中包含著年齡和抽煙,先天性的血栓障礙,外傷或外科手術痕,癌症,發炎性腸道疾病,心臟衰竭等。主要的治療藥,有血栓溶解劑和抗凝固劑等。

本報告提供全球各國的深部靜脈血栓症(DVT)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

深部靜脈血栓症 (DVT)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

深部靜脈血栓症 (DVT):企業開發中的治療藥

深部靜脈血栓症 (DVT):大學/機關研究中的治療藥

深部靜脈血栓症 (DVT):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

深部靜脈血栓症 (DVT):企業開發中的產品

深部靜脈血栓症 (DVT):大學/機關研究中的產品

深部靜脈血栓症 (DVT的)治療藥的開發企業

  • 3SBio Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Generex Biotechnology Corporation
  • Laboratorios Farmaceuticos Rovi, S.A.

深部靜脈血栓症 (DVT):治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

深部靜脈血栓症 (DVT):最近的開發平台趨勢

深部靜脈血栓症 (DVT):暫停中的計劃

深部靜脈血栓症 (DVT):開發中止的產品

深部靜脈血栓症 (DVT):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8505IDB

Summary

Global Markets Direct's, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016', provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)
  • The report reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Deep Vein Thrombosis (DVT) therapeutics and enlists all their major and minor projects
  • The report assesses Deep Vein Thrombosis (DVT) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Deep Vein Thrombosis (DVT) Overview
  • Therapeutics Development
    • Pipeline Products for Deep Vein Thrombosis (DVT) - Overview
    • Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis
  • Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies
  • Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes
  • Deep Vein Thrombosis (DVT) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Deep Vein Thrombosis (DVT) - Products under Development by Companies
  • Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes
  • Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Dong-A Socio Holdings Co. Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Generex Biotechnology Corporation
    • Laboratorios Farmaceuticos Rovi, S.A.
    • Pharmathen Pharmaceuticals S.A.
  • Deep Vein Thrombosis (DVT) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARC-15105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enoxaparin sodium biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enoxaparin sodium biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enoxaparin sodium biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fondaparinux sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-023725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Deep Vein Thrombosis (DVT) - Dormant Projects
  • Deep Vein Thrombosis (DVT) - Discontinued Products
  • Deep Vein Thrombosis (DVT) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer's Xarelto Accepted for Presentation at ESC Congress 2016
      • May 18, 2016: Janssen to Present Data on Rivaroxaban at the 2016 American Society of Clinical Oncology Annual Meeting
      • Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
      • Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials
      • Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
      • Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis
      • Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015
      • Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015
      • Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
      • May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis
      • Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents
      • Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
      • Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
      • Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
      • Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016
  • Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc., H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016
  • Deep Vein Thrombosis (DVT) - Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2016
  • Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016
  • Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top